https://www.selleckchem.com/pr....oducts/tyloxapol.htm
There was a time-dependent increase in trastuzumab Vc, positively correlated to baseline SUV . Bevacizumab elimination rate (k ) was positively correlated with ΔSUV measured at the end of the first cycle. Bevacizumab had no significantly influence on trastuzumab pharmacokinetics. No relationship between exposure and clinical response or occurrence of adverse events was found. Tumour uptake as assessed by SUV influences the pharmacokinetics of bevacizumab and trastuzumab. In early-stage breast cancer, elimination half-lives of these th
Like
Comment
Share
